Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Executive Summary
Updated on 7/12/2025
READ on the Legacy of LPBI Group as updated on 5/16/2025
- LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI
READ on Multimodal Healthcare Foundation Model as updated on 6/3/2025
- Multimodal Healthcare Foundation Model
Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content generated by LPBI Group’s Experts, Authors, Writers (EAWs) used as Training Data for the Model
https://pharmaceuticalintelligence.com/healthcare-foundation-model/
UPDATED on 4/30/2025
Looking to the future, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.
INTERACTIVE CHAT with Grok, created by xAI: LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director
For DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
Read also 2.0 LPBI Group
https://pharmaceuticalintelligence.com/2-0-lpbi-executive-summary/
UPDATED on 2/1/2021
The Challenge
“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, Ph.D., R.N., and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”
Updated 2020 Vision included 2.0 LPBI:
LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.
https://pharmaceuticalintelligence.com/vision/
About LPBI Group
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Since 2012, Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.
LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives. It offers real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Year over year, there is an increased readership of highly valued content, which equates to 5,900 scientific articles with +1.8Million views in the online scientific journal.
Unique, Experienced Team
The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine arenas.
All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed an interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes:
- Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
- Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Irina Robu, Dr. Aviva Lev-Ari. Other key contributors in 1.0LPBI Group’s past included Dr. Ritu Saxena, Dr. Tilda Barliya and Dr. Dror Nir
- Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada).
- Executives in Biotechnology and Information Technology Industries: Joel T. Shertok, ex-Sr. Exec VP at Amaco and Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy). Past affiliates of the business side at 1.0 LPBI Group included Mr. Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Mr. Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), and Ritu Saxena, PhD (Astellas Pharma),
Scientific e-Books Source
The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by continued online updates made to articles within the online scientific journal. Each of the scientific e-books contains an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.
Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.
Journal Ontology
Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:
eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model
Three Classes of Intellectual Property Assets
These assets include an open-access online scientific journal with curated, current biomedical research – a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.
For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.
The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.
The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate on-boarding and training.
Additional Details
Our venture moves across several industries. We have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house. The purpose is to mitigate the information explosion in the Life Sciences and information obsolescence. The content lends its attribution to electronic Scientific Publishing and to Pharmaceutical Media. It would be useful to review the business functions that this content contributes to by the value drivers in each economic segment
https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/
Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
[Figures as of August 12, 2020]
http://pharmaceuticalintelligence.com
- LPBI Scientific Journal: Open Access Online Scientific Journal with +1.9Million views, 5,900 scientific articles, 7,442 scientific comments by global scientists, 715 categories of research in the Journal’s ontology and 10,335 tags.
- BioMed e-Series: 16 Volumes in the frontiers of Life Sciences and Medicine, average volume size: 2,400 pages,
- Also, 113,716 page downloads in total on June 14, 2020, which is the equivalent of 49 books, plus the volumes that have been sold.
- e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time from 2013 to present by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference. ~40 Tweet Collections were generated in the last 4 years.
OTHER ASSETS
- Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
- Asset Class V is a Gallery of ~5000 images used in the articles and books
- Asset Class VI is the Team of Experts
- Asset Class VII: Royalties on BioMed e-Series
- Asset Class VIII: 2,540 Subscribers to the Journal
- Asset Class IX: Intangible Assets representing impressing e-Reputation
- Asset Class X: e-VOICES PODCASTING – Audio/Video Library
Updated 2020 Vision includes
The Pipeline and Plans for 2.0 LPBI: 2021 – 2025
https://pharmaceuticalintelligence.com/vision/
LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible. The challenge for the future is the development of several, i.e., the following six new strategies for creation of Value added Serivces and Products.
2.0 LPBI – 2021 and Beyond
The New Strategies: TNS #1, #2, #3, #4, #5, #6
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery:
- We worked together in 2015-2016 for 2 years – Plan for 2020-2021: Galectins explored as drugable by Scientists using Synthetic Biology to design new drug molecules
- 15 INTERNS are joining after Labor Day – they need to gain some LAB Flavor in return for working as Volunteers @LPBI projects: SEE
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
- 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) 9/2020 – 9/2021
TNS #6: e-Books Translations into Japanese, Spanish, Russian
FOR DETAILS SEE 1.0 LPBI BROCHURE
https://pharmaceuticalintelligence.com/1-0-lpbi-brochure/
for access send e-mail to
Aviva Lev-Ari@alum.Berkeley.edu
2012pharmaceutical
sjwilliamspa